| Similar Articles |
|---|
 |
The Motley Fool
January 22, 2007
Brian Lawler |
The Feds Eye Endo Endo Pharmaceuticals' sales practices for Lidoderm prompt government scrutiny. Investors don't seem too concerned.   |
Pharmaceutical Executive
May 1, 2012 |
Managing Information Overload Pharmaceutical companies know they need regulatory information management. What they don't always know is where to start and how to weave this vital capability across the enterprise. |
The Motley Fool
November 6, 2007
Brian Lawler |
The Two Sides of Endo It has been a mixed third quarter for Endo Pharmaceuticals. On the financial side of things the company performed well; on the research and development side, things are not as good. |
The Motley Fool
October 23, 2006
Brian Lawler |
Not the End for Endo An FDA decision won't hurt the maker of Lidoderm. Investors, take note. |
The Motley Fool
January 30, 2008
Brian Lawler |
The Endo a CEO Shares of Endo Pharmaceutical rise after its CEO, Peter Lankau, resigns. |
The Motley Fool
January 19, 2007
Brian Lawler |
The Best Drug Stock for 2007: Endo Pharmaceuticals This drug-maker just might be a great investment at the current price. |
Chemistry World
May 26, 2015
Phillip Broadwith |
Endo to buy Par as generics consolidation continues Irish-headquartered firm Endo Pharmaceuticals has agreed to buy private US firm Par Pharmaceuticals in a deal worth around $8 billion in a combination of cash, shares and assumed debt. |
The Motley Fool
April 30, 2007
Brian Lawler |
Nothing Wrong With Endo Endo Pharmaceuticals releases first-quarter financial results. Investors, take note. |
The Motley Fool
April 12, 2011
Arundhati Parmar |
Endo Acquires Pelvic Care Firm American Medical Systems The company that began life in the pharmaceutical sector is venturing forth into devices in its quest to become more of a diversified health-care company. |
The Motley Fool
October 3, 2007
Brian Lawler |
FDA Says Nay to Endo Endo Pharmaceuticals announces that the FDA issued a "not approvable" letter in response to the company's attempt to expand the label for migraine treatment Frova. |
The Motley Fool
April 1, 2008
Brian Lawler |
The Endo a Patent? Endo sues to protect a lead drug from generic competition. |
IndustryWeek
March 16, 2011
Ebert et al. |
Managing Regulatory Challenges in a Global Marketplace Meeting requirements in emerging markets makes regulatory compliance an increasingly difficult issue for manufacturers. A new study sheds light on the challenges and how leading companies are meeting them. |
The Motley Fool
December 30, 2010
Brian Orelli |
That's What You Call Product Differentiation? Endo Pharma misses the mark with its treatment for low testosterone, which the Food and Drug Administration approved yesterday. |
The Motley Fool
September 29, 2010
Brian Orelli |
A Mini-Teva in the Making Generic growth by Endo Pharmaceuticals. |
The Motley Fool
April 30, 2007
Brian Orelli |
No Pain for Endo's Investors Endo Pharmaceuticals had an impressive first quarter thanks to a new product and continued sales growth of its older brands. Investors, take note. |
The Motley Fool
August 1, 2007
Brian Lawler |
Calling Out Endo Endo Pharmaceuticals gets taken to task by an activist investor. An investment group owning 5.6% of outstanding shares is concerned with how management plans to use $700 million available to them in cash and investments. |
The Motley Fool
January 10, 2007
Brian Lawler |
Endo's Plan to Bring In the Dough Despite little movement in the value of their shares, 2006 was an eventful year for investors in drug developer Endo Pharmaceuticals. |
